Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


 

European Council Brings SPC Manufacturing Waiver A Step Closer

A proposed SPC manufacturing waiver – which would allow generic and biosimilar manufacturing within Europe during the SPC period – has taken a step closer to being realized after the European Council approved a mandate for negotiations with the European Parliament. However, it remains uncertain whether key elements desired by the off-patent industry will fall into place.

Europe Manufacturing Generic Drugs

Manufacturing Roundup – 17 January 2019

Dr Reddy’s is hit with a manufacturing setback after getting issued a Form 483 report for its site in Andhra Pradesh, India, while several firms announce site expansions, including in Spain and the US.

Companies Manufacturing United States

Belgium Unveils Incentives For Biosimilar Adalimumab And Etanercept

Belgium has introduced financial incentives to encourage doctors to prescribe anti-TNF biosimilars adalimumab and etanercept outside of hospitals.

Belgium Biosimilars Regulation
Advertisement

How to Drive Consistent and Long-Term Growth In the Off-Patent Pharma Arena

Read this new report which provides highlights from senior voices in the pharmaceutical and financial industry who participated in a roundtable in November at the House of Lords. Topics discussed include Brexit, moving up the value chain and much more.

View Report

Pharma Report Store

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop Now
 

Commercial Explore this Topic

Industry Veteran Haggar To Lead Private Equity-Backed Zentiva From Next Month

Only four months after it was carved out from Sanofi to become an independent company, Prague-based Zentiva has announced fresh leadership in the form of Nick Haggar, the 30-year industry veteran and former president of Medicines of Europe.

Appointments Europe

Pfizer Axes Staff And Five Pre-Clinical Biosimilars To Fund Late-Stage Innovative Programs

With an eye on moving to market its broad pipeline of innovative brands, Pfizer has cut development of five early-stage biosimilar assets, in a decision that will affect 150 staff. The move is not reflective of Pfizer's overall commitment to biosimilars, the US-based company maintains.

Strategy Biosimilars

Cipla Partners With Bio-Thera For Bevacizumab In Select Emerging Markets

Cipla has formed a licensing agreement with Bio-Thera Solutions for the Chinese firm’s BAT1706 bevacizumab biosimilar, which the Indian company will distribute and sell in select emerging markets.

Biosimilars Deals

Amneal Eyes Generic Injectables Deals, While Competition Bites Sooner Than Anticipated

A strengthened cash position has provided Amneal the chance to seek inorganic opportunities to bolster its growing presence in injectables. The US-based, US-centric company is looking to grow its operations, having been surprised in recent weeks by generic competition to its most lucrative generic assets.

Strategy Pricing Debate

Pfizer To Close Two Former Hospira Sites In India

Pfizer is set to close two of its manufacturing facilities in India this year, after the firm concluded that production at the former Hospira sites “is not viable” due to falling demand.

India Generic Drugs

Alvotech Advances Partnerships To Take Pipeline Global

By the middle of this year, biosimilars developer Alvotech plans to have strategic alliances in place with a handful of regional partners to commercialize its pipeline of seven biosimilar monoclonal antibodies.
Biosimilars Business Strategies
See All

Policy & Regulation Explore this Topic

Wockhardt Wins Review Of Ban On Indian Combination

Evidence put forward by manufacturers to support fixed-dose combinations must be considered by an advisory committee to India’s government, the Delhi High Court has ordered in a verdict favouring Wockhardt.
India Regulation

Remodulin And Revlimid Rivals Join France’s Répertoire

Almost 20 new generic groups – including rivals to Flecaine, Inegy, Remodulin and Revlimid – have been added to France’s répertoire of generic equivalents following the latest update by local medicines agency ANSM.

France Generic Drugs

FTC Grants Teva's Request To Reopen Watson-Actavis Merger

The FTC will allow Teva to continue to supply the Embeda brand to Pfizer in 2019, despite Teva having taken several years to bring its in-development generic version to market.

United States Regulation

Belgian Body Bolsters Awareness Of Biosimilars

Belgian medicines agency AFMPS has launched a public information campaign to educate patients on biologics and to encourage the uptake of biosimilars.

Belgium Regulation

FDA’s Gottlieb Rolls Out A Raft Of Biosimilar Reforms

As the FDA publishes several key guidance documents on biosimilars and biologics, Commissioner Scott Gottlieb has outlined the latest steps in the agency’s ongoing efforts to support the market. These include measures to address the abuse of REMS, as well as transitioning products such as insulin and human growth hormone into the biologics framework.

United States Biosimilars

Blocking Substitution Faces Tighter French Control

After a tug-of-war between the French Senate and Assemblée Nationale that saw controversial budget measures relating to generic substitution removed from draft legislation, a final version has been passed that reinstates them.

France Regulation
See All

Latest From Generic Drugs

Wockhardt Wins Review Of Ban On Indian Combination

Evidence put forward by manufacturers to support fixed-dose combinations must be considered by an advisory committee to India’s government, the Delhi High Court has ordered in a verdict favouring Wockhardt.
India Regulation

Remodulin And Revlimid Rivals Join France’s Répertoire

Almost 20 new generic groups – including rivals to Flecaine, Inegy, Remodulin and Revlimid – have been added to France’s répertoire of generic equivalents following the latest update by local medicines agency ANSM.

France Generic Drugs

Court Clears Teva After At-Risk Budesonide Entry

Teva has escaped potential damages from its ‘at risk’ US launch of budesonide extended-release tablets after a US Court of Appeals upheld a previous non-infringement ruling.
Intellectual Property Gastrointestinal
See All

Latest From Biosimilars

Switching Studies Show Safety Of Celltrion's Infliximab Biosimilar In IBD

Two infliximab switching studies have provided reassuring data on the safety of Celltrion’s CT-P13 infliximab biosimilar to treat IBD. While one report explores changing pediatric patients to CT-P13 from the Remicade reference drug, the other looks at reverse switching patients from the biosimilar to the originator brand.

Biosimilars Market Intelligence

Pfizer Axes Staff And Five Pre-Clinical Biosimilars To Fund Late-Stage Innovative Programs

With an eye on moving to market its broad pipeline of innovative brands, Pfizer has cut development of five early-stage biosimilar assets, in a decision that will affect 150 staff. The move is not reflective of Pfizer's overall commitment to biosimilars, the US-based company maintains.

Strategy Biosimilars

Cipla Partners With Bio-Thera For Bevacizumab In Select Emerging Markets

Cipla has formed a licensing agreement with Bio-Thera Solutions for the Chinese firm’s BAT1706 bevacizumab biosimilar, which the Indian company will distribute and sell in select emerging markets.

Biosimilars Deals
See All

Latest From Value-Added Medicines

Sandoz Phases US Epinephrine Entry

Sandoz will first focus on the US institutional channel on which it is increasingly concentrating its attention as it rolls out its alternative to Mylan’s EpiPen epinephrine auto-injector.
Value-Added Medicines Launches

Dr Reddy’s Growth Strategy Sets Sights On Six Spaces

Dr Reddy’s chief operating officer Erez Israeli says six key areas – the US, China, Russia, India, APIs and hospital drugs – underpin the Indian company’s growth ambitions, with small-molecule generics remaining the firm’s “bread and butter”.

United States India

Kashiv Pharma Swallows Up Adello Biologics, Becoming Kashiv BioSciences

New Jersey-based Kashiv adds biosimilar assets to its repertoire by acquiring Adello Biologics, becoming, in its own words, a “fully-integrated biosciences company with an expanded and dynamic platform for growth.” Adello’s CEO, Chintu Patel, will lead the combination.

M & A Biosimilars
See All
UsernamePublicRestriction

Register

Advertisement